Combination immunotherapy: a road map
Patrick A. Ott(Dana-Farber Cancer Institute), Jedd D. Wolchok(Cornell University), Jon M. Wigginton(Bristol-Myers Squibb (United States)), F. Stephen Hodi(Harvard University), Howard L. Kaufman(Rutgers, The State University of New Jersey)
Cited by 381
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k